Published in Clin Immunol Immunopathol on February 01, 1978
Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. Am J Pathol (1983) 1.51
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest (1982) 1.20
Epstein-Barr-virus-carrying lymphoma in a patient with ataxia-telangiectasia. Br Med J (Clin Res Ed) (1981) 0.98
Selective immunodeficiency and malignant lymphoma of the central nervous system. Possible relationship to the Epstein-Barr virus. Acta Neuropathol (1979) 0.90
Hypothesis: the pathogenesis of AIDS. Activation of the T- and B-cell cascades. Yale J Biol Med (1984) 0.88
Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue. J Clin Pathol (1990) 0.87
Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease. Clin Exp Immunol (1991) 0.81
Effects of nucleoside analogs on Epstein-Barr virus-induced transformation of human umbilical cord leukocytes and Epstein-Barr virus expression in transformed cells. Antimicrob Agents Chemother (1979) 0.77
Lymphocyte function and disease. Br Med J (1978) 0.77
Genetics of neoplasia--impact of ecogenetics on oncogenesis. A review. Am J Pathol (1978) 0.76
Failure to demonstrate concomitant antibody changes to viral antigens other than Epstein-Barr virus (EBV) during or after infectious mononucleosis. Yale J Biol Med (1984) 0.75
The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med (1969) 4.96
Depressed maternal lymphocyte response to phytohaemagglutinin in human pregnancy. Lancet (1972) 4.47
Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest (1967) 4.45
In search of Methuselah: estimating the upper limits to human longevity. Science (1990) 3.99
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Primary immunodeficiencies. Report of a World Health Organization Committee. Pediatrics (1971) 3.69
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Aberrations of suppressor T cells in human graft-versus-host disease. N Engl J Med (1979) 3.10
Homozygous deficiency of C3 in a patient with repeated infections. Lancet (1972) 3.04
The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med (1966) 3.03
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest (1970) 2.92
Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity (1998) 2.92
N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol (2001) 2.91
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology (2003) 2.80
Fatal strongyloidiasis in immunosuppressed patients. Am J Med (1974) 2.76
Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol (1987) 2.74
Heterogeneity of "acquired" or common variable agammaglobulinemia. N Engl J Med (1974) 2.69
X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet (1975) 2.57
Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 2.51
The opsonic fragment of the third component of human complement (C3). J Exp Med (1975) 2.51
Global gene profiling in human endometrium during the window of implantation. Endocrinology (2002) 2.48
Abnormalities of immunoregulatory T cells in disorders of immune function. N Engl J Med (1979) 2.48
Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N Engl J Med (1982) 2.47
Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med (1982) 2.44
Implantation of a foetal thymus, restoring immunological competence in a patient with thymic aplasia (Digeorge's syndrome). Lancet (1968) 2.40
Cellular and humoral immunity to different types of human neoplasms. Nature (1968) 2.40
Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med (1975) 2.35
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A (1969) 2.28
Serum-dependent phagocytosis of paraffin oil emulsified with bacterial lipopolysaccharide. J Exp Med (1973) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Cdc42 is required for PIP(2)-induced actin polymerization and early development but not for cell viability. Curr Biol (2000) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med (1973) 2.17
Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med (1970) 2.08
The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments. J Exp Med (1970) 2.05
Identification and characterization of subpopulations of lymphocytes in human peripheral blood after fractionation on discontinuous gradients of albumin. The cellular defect in X-linked agammaglobulinemia. J Clin Invest (1973) 2.05
Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome. N Engl J Med (1977) 2.01
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98
Nephrogenic fibrosing dermopathy. Am J Dermatopathol (2001) 1.91
Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med (1977) 1.85
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest (1971) 1.83
Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med (1970) 1.80
Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev (1988) 1.78
Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood (2000) 1.78
Hereditary angioneurotic edema: a clinical survey. Pediatrics (1966) 1.75
The primary immunodeficiencies (1). N Engl J Med (1984) 1.74
Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. Proc Natl Acad Sci U S A (1989) 1.73
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Nursing home residents need physicians' services. Ann Intern Med (1994) 1.69
Characterization of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Exp Med (1984) 1.68
Accidental nuclear war--a post-cold war assessment. N Engl J Med (1998) 1.66
The hybrid epidermoid and apocrine cyst. A combination of apocrine hidrocystoma and epidermal inclusion cyst. Am J Dermatopathol (1996) 1.64
Expression on blood cells of sialophorin, the surface glycoprotein that is defective in Wiskott-Aldrich syndrome. Blood (1987) 1.64
Rapid detection of cytomegalovirus by tissue culture, centrifugation, and immunofluorescence with a monoclonal antibody to an early nuclear antigen. J Virol Methods (1987) 1.63
Deficiency of suppressor T cells in the hyperimmunoglobulin E syndrome. J Clin Invest (1981) 1.63
Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci U S A (1996) 1.62
Sialophorin, a surface sialoglycoprotein defective in the Wiskott-Aldrich syndrome, is involved in human T lymphocyte proliferation. J Exp Med (1987) 1.61
CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature (1991) 1.60
Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B. Clin Immunol Immunopathol (1973) 1.60
Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep (1997) 1.60
T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol (1993) 1.59
Partial Xq25 deletion in a family with the X-linked lymphoproliferative disease (XLP) Cancer Genet Cytogenet (1990) 1.58
Congenital cardiovascular disease and anomalies of the third and fourth pharyngeal pouch. Circulation (1972) 1.57
Inherited deficiency of the third component of human complement (C'3). J Clin Invest (1969) 1.56
Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. Blood (1987) 1.56
Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol (1999) 1.53
The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery (1981) 1.53
Morphological abnormalities in the lymphocytes of patients with the Wiskott-Aldrich syndrome. Blood (1986) 1.53
Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol (1997) 1.52
Genetic aspects of the complement system. Adv Immunol (1971) 1.52
Laser resurfacing-induced hypopigmentation: histologic alterations and repigmentation with topical photochemotherapy. Dermatol Surg (2001) 1.51
Abnormalities of T cell maturation and regulation in human beings with immunodeficiency disorders. J Clin Invest (1981) 1.50
Congenital aplasia of the thymus gland (DiGeorge's syndrome). N Engl J Med (1968) 1.49
Mapping of the X-linked agammaglobulinemia locus by use of restriction fragment-length polymorphism. J Clin Invest (1986) 1.49
Hematopathologic features of Epstein-Barr virus-induced human B-lymphoproliferation in mice with severe combined immunodeficiency. A model of lymphoproliferative diseases in immunocompromised patients. Lab Invest (1991) 1.48
Letter: Fatal infectious mononucleosis in familial lymphohistiocytosis. N Engl J Med (1974) 1.46
Beta-1C-globulin: metabolism in glomerulonephritis. Science (1966) 1.45
Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proc Natl Acad Sci U S A (1982) 1.44
Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med (1972) 1.44
The primary immunodeficiencies. (2). N Engl J Med (1984) 1.43
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol (1999) 1.42
Cellular reactivity to Candida albicans antigen. N Engl J Med (1966) 1.41
Burn scar carcinoma. Diagnosis and management. Dermatol Surg (1998) 1.40
The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med (1966) 1.40
Classification of the primary immune deficiencies: WHO recommendation. N Engl J Med (1970) 1.39
Benign sebaceous neoplasm with prominent epidermal component. Am J Dermatopathol (1998) 1.38
Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. Int Rev Exp Pathol (1985) 1.35
Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med (1978) 1.35